RxDoctor Payments Data

Ngan Nguyen

Family · Clifton Park, NYNPI 1336887587

Payments from drug & device makers

$1,978in general payments, 2019–2025

Across 89 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$451
  • Novo Nordisk$289
  • Lilly USA, LLC$229
  • Abbott$221
  • AstraZeneca$182
  • GSK$128
  • plus $478 from 11 others

What the payments were for

  • Food & beverage$1,978100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,978 in reported general payments places this provider in the 80th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$133,359
Medicare patients
613
Services billed
981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$76,839
JardianceEmpagliflozin25$27,826
EliquisApixaban25$22,520
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,307
JanuviaSitagliptin Phosphate11$11,076
MyrbetriqMirabegron16$8,847
Tresiba Flextouch U-100Insulin Degludec18$8,717
SynthroidLevothyroxine Sodium42$3,443
Albuterol Sulfate HfaAlbuterol Sulfate97$2,729
Atorvastatin Calcium186$1,614
Levothyroxine Sodium97$1,498
Rosuvastatin Calcium78$1,151
Omeprazole78$1,102
Gabapentin51$738
Diclofenac Sodium26$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$289$76,83961 claims
GSKTrelegy Ellipta$128$11,30717 claims
MerckJanuvia$47$11,07611 claims
Astellas Pharma US IncMyrbetriq$84$8,84716 claims
AbbVieSynthroid$451$3,44342 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$1,49897 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,883 family providers in New York.

Other family in Clifton Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →